BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

March 18, 2013 7:00 AM UTC

Biogen Idec Inc. (NASDAQ:BIIB) gained $4.40 to $176.78 last week after submitting a BLA to FDA for rFVIIIFc to treat hemophilia A. The product is partnered with Swedish Orphan Biovitrum AB (SSE:SOBI), which gained SEK4.10 (11%) to SEK42 last week.

Endo Health Solutions Inc. (NASDAQ:ENDP) was down $0.57 to $30.68 on Friday after FDA's Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committees announced plans to meet on April 18 to discuss an NDA for Aveed testosterone undecanoate to treat male hypogonadism. Endo resubmitted the NDA last November. The company said the PDUFA date is in May, but did not disclose a specific date...